Monte Rosa Therapeutics, Inc.
GLUEDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
GLUE Earnings Report
EPS Est: $-0.25 | FQ end 2026-06
How GLUE's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oral MRT-2359 | Phase 2 | NSCLC | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Monte Rosa Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Monte Rosa Therapeutics, Inc.'s (GLUE) pipeline across Phase 2. Its lead program is Oral MRT-2359 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Monte Rosa Therapeutics, Inc.'s next FDA catalyst?→
Monte Rosa Therapeutics, Inc.'s (GLUE) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GLUE biotech catalysts?→
Add GLUE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Monte Rosa Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.